<DOC>
	<DOCNO>NCT02974855</DOCNO>
	<brief_summary>This study design evaluate safety , tolerability , pharmacokinetics , pharmacodynamics efficacy multiple subcutaneous and/or intravenous dose PF-06741086 subject severe hemophilia .</brief_summary>
	<brief_title>PF-06741086 Multiple Dose Study Severe Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Severe hemophilia A B ( Factor VIII Factor IX activity â‰¤ 1 % ) know Factor VIII Factor IX inhibitor Episodic ( ondemand ) treatment regimen prior screen At least 6 acute bleed episode 6month period prior screen Known coronary artery , thrombotic , ischemic disease Detectable document history inhibitor Factor VIII Factor IX 12month period prior screen Concomitant treatment rFVIIa activate prothrombin complex concentrate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hemophilia</keyword>
</DOC>